China's first self -developed domestic crown disease small molecule oral special effects drugs were approved to be listed.
According to the portal of the Henan Provincial People's Government Portal, on Tuesday (July 26), China developed by Henan Real Biotechnology Co., Ltd. to have a small crown disease with complete self -contained intellectual property rights and global patentAzvudine was approved for listing on Monday (25th).
Sources said that this drug was used as the inventor by Henan Normal University, Zhengzhou University Chang Junbiao, and united Henan Real Biotechnology Co., Ltd.A subsidiary hospital and other scientific research teams have completed R & D and clinical trials for more than two years.
The news also states that Azf has strong targeted and long -acting, has the advantages of low oral dosage, good effect, small side effects, and wide adaptation range.The intensiveness is effective, and it has obvious effects on the coronary virus mutation strain (Alpha, Beta, Delta, Omikon), which is expected to become the preferred drug for crown disease in the future.
According to the official website of the National Pharmaceutical Supervision and Administration Bureau of China, this time Azf was approved as "Emergency Conditional Approval" and requested that the listing holders to continue to carry out related research work and complete the attachment within a time limit to complete the attachment within a time limit.The requirements for conditions will be submitted in a timely manner.
Sources said that the China State Drug Administration had attached conditions to approve Azfding with other reverse-transient enzyme inhibitors in July 2021 to treat adult HIV-1 infection patients with high virus load;This is an attachment to approve new indications for the treatment of adult patients in ordinary crown diseases.
Data show that Phaxlovid's Paxlovid is the only crown -related small molecule oral medicine in the Chinese market.
